Gene therapy: why control the amount of MECP2?
Understanding a preclinical paper on NGN‑401.
Results presented
The paper describes an EXACT system intended to regulate MECP2 expression. The results concern cells, Rett mouse models and non-human primates, not efficacy in participants.
Preclinical: cell assays, Mecp2 mouse models and non-human primates; no human participant in this article.
Compared with vehicle or conventional construct depending on experiment; the associated human trial is NCT05898620.
EXACT-MECP2 reduced expression variability; NGN-401 prolonged survival and improved phenotypes in Mecp2-/y mice.
No human AEs. NGN-401 was well tolerated in female Mecp2+/- mice and juvenile primates; the conventional construct caused toxicity.
Publisher funding information: Neurogene Inc. Potential conflicts should be read in the publisher article.
Animal → human translation is not demonstrated. RE2T does not present NGN-401 as an available treatment.
RE2T record: documentary writing by RE2T, primary source checked, AI-assisted translation. Editorial review still to complete; no medical validation claimed.
RE2T Recherche · source-controlled-ai-assisted-editorial-pending-no-medical-validation
Limits to keep in mind
Preclinical results only: they support a human study but do not show clinical benefit or treatment access.
Original title (English)
Self-regulating gene therapy ameliorates phenotypes and overcomes gene dosage sensitivity in a mouse model of Rett syndrome
Ross PD et al. · Science Translational Medicine
Online publication · Apr 2, 2025
PMID 40173263
DOI 10.1126/scitranslmed.adq3614
Related study
NGN‑401 · Embolden
Consulted · Sep 8, 2026
Sources consulted on 8 September 2026 · AI-assisted summaries and translations, not medically validated.